Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Subcutaneous blinatumomab in pediatric R/R and MRD+ B-ALL
2025-521671-31-00Phase 2Authorised
- Sponsor
- Amgen
- Start
- Feb 2026
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, scFv Fragments → Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 9
01
Overview
Phase 2, open-label trial of blinatumomab in acute lymphoblastic leukemia (ALL) and B cell acute lymphoblastic leukemia (B-ALL) (3 arms), sponsored by Amgen. Primary endpoints: Phase 1b: Dose limiting toxicities and safety profile, Phase 2 (Cohort Ph2-R): Complete remission/complete remission with partial hematological recovery and 1 more. Planned start Feb 2026; status: authorised.
02
Drugs
blinatumomab
03
Conditions
acute lymphoblastic leukemia (ALL)B cell acute lymphoblastic leukemia (B-ALL)
Beyond the preview
Go deeper on 2025-521671-31-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-521671-31-00.